Trusted worldwide for providing teams with quick and easy access to the most up to date medicines information

 

Our respected publications available through MedicinesComplete, provide you with expert and unbiased knowledge to support you make confident decisions on the use and administration of medicines. Essential resources are referred to daily across healthcare, academic, research settings, and are relied on by many commercial organisations to operate their businesses.

Since the launch of MedicinesComplete, we continue to expand our trusted portfolio of core and specialist resources, as well as clinical checkers and calculators to support healthcare professionals to make confident decisions at the point of care. Our latest resources include Critical Illness, essential medicines information to support complex decision-making and dynamic prescribing in critical care and Drug Monitoring Checker, a practical and searchable point-of-care tool providing evidence-based, actionable monitoring information to optimise drug treatment.

Subscribe Publication Updates

Publication Updates

13 Sep
British National Formulary logo
British National Formulary September 2022 Update

This update contains 9 significant changes, 6 new monographs, and 1 deleted preparation.

Significant Changes:
• Controlled drugs and drug dependence: updated guidance on the prescribing of drugs associated with dependence and withdrawal.
• Cystic fibrosis transmembrane conductance regulator modulators: update to hepatic impairment advice (see example in ivacaftor).
• Dexmedetomidine: clinical trial finds increased risk of mortality in intensive care unit (ICU) patients aged 65 years or younger [MHRA/CHM advice].
• Epilepsy: updated guidance on management.
• Hydrocortisone: addition of children’s dosing for adrenal crisis.
• Immunisation schedule: updated guidance for immunisation against influenza.
• Influenza vaccine: updated guidance for immunisation.
• Tezacaftor with ivacaftor and elexacaftor: name change to ivacaftor with tezacaftor and elexacaftor.
• Topiramate (Topamax®): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure [MHRA/CHM advice].

New Monographs:
Aklief® [trifarotene].
Brukinsa® [zanubrutinib].
• Magnesium citrate.
NovoThirteen® [factor XIII A-subunit (recombinant)].
Padcev® [enfortumab vedotin].
Palforzia® [peanut protein].

Deleted Preparation:
• Codeine phosphate solution for injection.

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699

13 Sep
Handbook on Injectable Drugs logo
ASHP Injectable Drug Information September 2022 Update

This update contains 5 new monographs, 92 revised monographs and 1 file.

New monographs: Bebtelovimab; Cilgavimab; Chloroprocaine Hydrochloride; Sildenafil Citrate; Tixagevimab

Revised monographs: Acyclovir Sodium; Alprostadil; Alteplase; Amiodarone Hydrochloride; Ampicillin Sodium; Ampicillin Sodium-Sulbactam Sodium; Aprepitant; Bamlanivimab; Bumetanide; Bupivacaine Hydrochloride; Calcium Chloride; Calcium Gluconate; Cangrelor Tetrasodium; Casirivimab-Imdevimab; Caspofungin Acetate; Cefiderocol Sulfate Tosylate; Ceftazidime; Ceftriaxone Sodium; Cilgavimab; Cisatracurium Besylate; Chlorpromazine Hydrochloride; Clonidine Hydrochloride; Cyclizine Lactate; Cytarabine; Dacarbazine; Daptomycin; Daunorubicin Hydrochloride; Dexamethasone Sodium Phosphate; Dexmedetomidine Hydrochloride; Diamorphine Hydrochloride; Diazepam; Diltiazem Hydrochloride; Diphenhydramine Hydrochloride; Dobutamine Hydrochloride; Dopamine Hydrochloride; Droperidol; Enoxaparin Sodium; Epinephrine Hydrochloride; Epirubicin Hydrochloride; Etesevimab; Etoposide Phosphate; Famotidine; Fat Emulsion, Intravenous; Fentanyl Citrate; Fluconazole; Fluorouracil; Gentamicin Sulfate; Haloperidol Lactate; Heparin Sodium; Hydromorphone Hydrochloride; Idarubicin Hydrochloride; Iohexol; Irinotecan Hydrochloride; Ketamine Hydrochloride; Lacosamide; Levetiracetam; Levocarnitine; Levofloxacin; Lidocaine Hydrochloride; Lorazepam; Mannitol; Mesna; Methadone Hydrochloride; Methotrexate Sodium; Metoclopramide Hydrochloride; Metronidazole; Milrinone Lactate; Morphine Sulfate; Nitroglycerin; Norepinephrine Bitartrate; Ondansetron Hydrochloride; Potassium Acetate; Propofol; Protamine Sulfate; Ranitidine Hydrochloride; Remdesivir; Rocuronium Bromide; Ropivacaine Hydrochloride; Sodium Acetate; Sodium Bicarbonate; Sodium Nitroprusside; Sotrovimab; Sufentanil Citrate; Tetracaine Hydrochloride; Theophylline; Tixagevimab; Tobramycin Sulfate; Vancomycin Hydrochloride; Vasopressin; Verapamil Hydrochloride; Vincristine Sulfate; Ziconotide Acetate.

Other file: ASHP Injectable Drug Information – Users Guide.

13 Sep
Palliative Care Formulary September 2022 Update

This update contains 1 revised monograph.

The following monograph has undergone minor revision:
Potassium

13 Sep
Agilio: Diagnosis and Treatment Guidance September 2022 Update

This update contains 1 new topic, 4 significant changes and 20 minor changes.

New Topic
• Integrated health and social care for people experiencing homelessness — this is a new Agilio topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.

Significant Changes
• Gonorrhoea — reviewed. A literature search was conducted in July 2022 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made.
• Hypertension — reviewed. A literature search was conducted in July 2022 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic is now fully in line with the National Institute for Health and Care Excellence (NICE) guideline Hypertension in adults: diagnosis and management and includes recommendations for adults with type 2 diabetes. As updates had already occurred to align with the NICE guideline, no major new changes to the recommendations have been made. Minor restructuring changes have been made.
• Melanoma — reviewed. A literature search was conducted in July 2022 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. Minor structural changes have been made to this topic, recommendations on non-melanoma lesions have been removed and the topic title has been changed to Melanoma. There have been no major changes to the recommendations.
• Multiple sclerosis — reviewed. Updated to align with NICE [NG220] Multiple sclerosis in adults: management. No major changes to recommendations have been made.

Minor Changes
• Glaucoma — minor update. Added a link to the NHS England Decision support tool.
• Urinary tract infection – children — minor update. This topic has been updated with the NICE quality standards covering Urinary tract infection in children and young people.
• Feverish children – risk assessment — minor update. This topic has been updated with the NICE quality standards covering Fever in under 5s.
• Feverish children – management — minor update. This topic has been updated with the NICE quality standards covering Fever in under 5s.
• Impetigo -– minor update. A minor typographical error has been corrected.
• Immunizations – seasonal influenza — minor update. The management section has been updated to align with the NHS immunisation programme 2022 to 2023.
• Dupuytren’s disease — minor update. Added NHS England Decision support tool link.
• Carpal tunnel syndrome — minor update. Added link to the NHS England Decision support tool.
• Osteoarthritis — minor update. Added link to NHS England Decision support tools.
• Atrial fibrillation — minor update. Added a link to the NHS England Decision support tool.
• Cataracts — minor update. Added a link to the NHS England Decision support tool.
• Macular degeneration – age related — minor update. Added link to NHS England Decision support tool.
• Bipolar disorder — minor update. Removed prothrombin time as an annual monitoring requirement for sodium valproate.
• Smoking cessation — minor update. Added information relating to the Allen Carr Easyway seminar programme. Added information about the lack of availability of varenicline until further notice.
• Post-traumatic stress disorder — minor update. Typographical error corrected.
• Immunizations – childhood — minor update. UK and international immunisation schedule comparison tool has been added to the ‘unknown immunization history’ sections.
• Lipid modification – CVD prevention — minor update. A recommendation to consider offering inclisiran has been added in line with the NICE technology appraisal Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia.
• Hypercholesteraemia – familial — minor update. Recommendations on offering inclisiran and bempedoic acid have been added in line with the NICE technology appraisals Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidemia and Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia.
• Neuropathic pain – drug treatment — minor update. Information that people taking pregabalin should be monitored for suicidal ideation and discontinuation considered in suspected cases has been added to this topic in line with the updated Summary of Product Characteristics.
• Diabetes – type 1 — minor update. Recommendations on blood pressure targets have been updated, and recommendations on providing advice about periodontitis have been added in line with the updated NICE guideline Type 1 diabetes in adults: diagnosis and management.

13 Sep
AHFS Drug Information logo
AHFS September 2022 Update

This update contains 2 new monographs and 16 revised monographs.

New monographs: Ganaxolone; Vutrisiran

Revised monographs: Alectinib; Bosutinib; Cabozantinib; Decitabine and Cedazuridine, Erdafitinib, Inotersen, Lanreotide; Lemborexant; Osimertinib; Patisiran; romiPLOStim; Ruxolitinib; Sarilumab; SORAfenib; Suvorexant; Tecovirimat.

13 Sep
Drug Monitoring Checker September 2022 Update

This update contains 5 new monographs, and 14 minor updates.

New monographs: Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole sodium.

Minor updates: Clobazam; Ethosuximide; Galantamine; Lamotrigine; Levetiracetam; Lithium carbonate; Rivastigmine; Sodium valproate; Tiagabine; Valproic acid; Venlafaxine; Vigabatrin; Zonisamide; Zopiclone.

View more